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1.1 Purpose of review  
 
Antibody-mediated rejection (AMR) currently represents one of the main problems for 
clinical management of heart transplant because of its diagnostic complexity and poor 
evidences supporting treatments.  
1.2 Recent findings  
 
Disorder-based diagnosis is a cornerstone in defining AMR. The limitations of the current 
classification have been partially overcome by novel studies improving the description of 
the immune-pathological graft abnormalities, and by new molecular approaches allowing a 
better understanding of the mechanisms behind AMR and of its relationship with cellular 
rejection and chronic vasculopathy. In-depth characterization of donor-specific antibodies 
showed to provide additional prognostic information and guide for treatment. Clinical 
relevance of AMR is bound to appropriate detection of graft dysfunction. In addition to 
traditional longitudinal evaluation by echocardiogram, cardiac magnetic resonance and 
detection of cell-free DNA may represent novel sensitive markers for graft injury that could 
prompt treatment before dysfunction becomes clinically manifest.  
1.3 Summary  
 
Despite improvements in the diagnostic process, therapeutic strategies made little 
progress in addition to the consolidation of practices supported by limited evidences. Novel 
complement inhibitors appear promising in changing this scenario. Nevertheless, 
collaborative multicenter studies are needed to develop standardized approaches tailored 
to the highly variable clinical and laboratory features of AMR.  
1.4 Introduction  
 
Although improvements in immunosuppressive therapies have significantly reduced 
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the frequency and clinical relevance of cell-mediated rejection (CMR) after heart 
transplantation, antibody-mediated rejection (AMR) has emerged as a major threat 
and conundrum for patient management, because of the still sizeable uncertainties 
beyond its pathogenesis, diagnosis and management [1n, 2].  
The reported incidence of AMR may vary widely, ranging from 3 to 85% [1n], 
because of the diverse diagnostic criteria, including pathological and/or clinical 
findings, and variations in screening frequency. Standardized pathology diagnostic 
criteria have improved the characterization of AMR and have also increased the 
recognition of the high variability in its clinical presentation. For example, AMR has 
been described as an acute and early-onset process responsive to treatment, but 
also as a hidden phenomenon that may be responsible for late and chronic graft 
dysfunction in patients long after transplant, usually poorly responsive to any 
treatment [3n]. In addition, antibodies – the key pathogenetic feature of AMR – may 
not be found in all patients with clinical and pathological evidence of AMR, whereas 
they may be assayed in clinically silent patients [4]. To further complicate the 
process definition, patients with biopsy-proven CMR may often show at least some 
of AMR features, leading to the diagnosis of ‘mixed’ rejection, a concept still unclear 
in terms of definition and treatment (e.g. is it a coexistence of two different 
rejections? Is it a false positive for AMR? Is a cellular infiltrate in the context of 
AMR?) [5nn, 6nn].  
In this article, we aim to dissipate some of the ambiguities surrounding AMR by 
discussing recent concepts going beyond its pathogenesis, diagnosis and 
treatment, and at the same time to highlight the most urgent unmet needs that 
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require future research.  
1.5 Pathogenesis 
 
AMR develops when the recipient’s allogeneic immune response triggers the 
production of donor-specific antibodies (DSAs) directed against human leukocyte 
antigens (HLAs) or other non- HLA antigens that may be expressed by the graft 
endothelium.  
The injury mediated by HLA-directed antibodies (HLA-Abs) is caused by multiple 
effector mechanisms, one of the best known of which is the activation of the 
complement cascade. Complement activation produces chemoattractants and 
proinflammatory mediators and ultimately leads to the synthesis of the membrane 
attack complex (MAC) formation. When directed against allograft endothelium, this 
immune-mediated storm causes acute injury with increased vascular permeability, 
vasculitis and microvascular thrombosis, ultimately leading to myocyte injury and 
graft dysfunction [7,8n]. Due to their local proinflammatory properties, complement 
early proteins appear to be more responsible for complement-associated injury than 
the MAC complex is.  
Not all DSA-induced injury is mediated by complement activity: although IgG 
subclass 3 are the strongest complement activator, IgG4 usually have little or no 
complement activity and are often linked with IgG2 as ‘noncomplement fixing’ [8&]. 
Of note, immune response against HLA epitopes is usually polyclonal, thus 
involving multiple IgG subclasses and multiple mechanisms of injury. In this 
context, the obligatory link between AMR and complement has recently become 
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controversial, and AMR occurrence has been recognized even in absence of 
complement capillary deposition [7,9]. This paradigm shift was driven by gene 
expression profiling analyses showing that AMR signature was present in C4d-
negative specimens [10] and is mirrored by experimental studies showing that 
intimal thickening during antibody-induced chronic rejection occurred in 
complement-deficient murine recipients, suggesting that there was no requirement 
for complement in this process [11]. In this process, the mammalian target of 
rapamycin (mTOR) signaling appears to play a key role, as it is activated by the 
HLA-Ab cross-linking on the surface of endothelial cells [12]. In addition to 
activating endothelial signals, Abs function by themselves as chemoattractant for 
monocytes, macrophages, neutrophils and natural killer (NK) cells, which all 
express receptors for the Fc region This direct cross-linking between antibodies 
and immune cells that can be recognized as infiltrating the graft tissue in biopsies 
may at least in part help to elucidate the conundrum of mixed rejection.  
Some patients with DSA do not show histological or clinical evidence of AMR [4], 
suggesting that other factors influence susceptibility to or risk of rejection in the 
presence of antibodies that bind the graft. Endothelial cells may be the mediators of 
this susceptibility and act as immune regulators by expressing of complement 
regulatory proteins, with variable response to injury, ranging from acute lytic injury 
to chronic nonlytic injury characterized by cytoskeleton disruption and expression of 
surface procoagulant molecules: these different responses are closely associated 
with different clinical presentations and response to therapy [3n,13].  
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1.6 Antibody-mediated rejection diagnosis: a complex 
multiparametric disease  
 
Although cellular rejection diagnosis is defined by the histologic description of the 
nature of the inflammatory infiltrate and myocyte damage found in endomyocardial 
biopsies (EMBs), the diagnosis of AMR would require clinical evidence of allograft 
dysfunction, pathology evidence of both morphologic and immunopathologic 
microvascular injury on EMB, in which the main immunopathology is the capillary 
deposition of complement degradation product C4d, and evidence of circulating 
DSA. Despite the prognostic importance of any one of the three components 
[14,15n], in clinical practice coexistence of at least two of them is required to plan a 
specific treatment [16]. In this section, we will revise the improvements and pitfalls 
of the current diagnostic system for AMR.  
1.6.1 Antibody-mediated rejection pathology classification and 
beyond  
 
A working formulation for pathologic diagnosis of AMR first appeared in 2011, and 
in 2013 the pathological classification and grading (pAMR) was published. This 
included the concept of complement- negative AMR, that is pAMR may be 
diagnosed when more than 10% of capillaries are found filled with CD68þ 
macrophages, even in absence of capillary C4d deposition [7]. Additional markers 
of micro- circulatory inflammation appear to further obviate any need for C4d 
detection, which is becoming increasingly meaningless as isolate finding [17]. In a 
prospective study, Tible et al. [18] found that immunostaining in capillary endothelial 
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cells for phosphorylated S6 kinase and 6S ribosomal protein (pS6RP and 
p70S60K), two targets of mTOR effectors, were correlated with microvascular 
inflammation and DSA. This finding has been independently replicated by Li et al. 
[19], who described in 107 patients that these markers of endothelial inflammation 
were more often associated with AMR features than C4d alone.  
In addition to the markers of endothelial activation, a number of studies introduced 
the concept of microvascular inflammation, histologically characterized by the 
presence of intravascular-activated mononuclear cells, including both intravascular 
macrophages and swollen endothelial cells [20]. In a multiinstitutional study, 
Fedrigo reports how the microvascular inflammatory burden that is extravascular 
interstitial and intravascular inflammatory cells was a constant feature of AMR and 
correlated with pAMR, C4d positivity and DSA positivity. In pAMR+ specimens, 
equivalent numbers of T lymphocytes and macrophages were seen in the 
intravascular and extravascular compartments. The presence of plasma cells was 
associated with a higher inflammatory burden and longer time post-transplant [5nn]. 
These findings mirror a more complex report from the UTAH group, which was 
trying to solve the conundrum of mixed rejection. After reviewing over 28 000 
EMBs, Kfoury et al. [6nn] found that pathology mixed features may often point to an 
overlap between pAMR and CMR, that relapsing CMRs are accompanied by 
progressive pAMR features and that mixed rejection portends a worse prognosis as 
compared with CMR or pAMR alone.  
Although improving AMR diagnostic accuracy of EMB, the addition of further 
histologic and immunopathologic evaluation criteria might well increase the 
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likelihood of interpathologist variability in reading and interpretation a well known 
and documented pitfall of disorder-based diagnosis of rejection [21]. Molecular 
biology analysis on myocardial tissue, on the other hand, may potentially progress 
the knowledge on the pathogenesis of rejection process and offer novel views to 
improve the diagnostic potential of EMBs. Afzali et al. [22nn] found that in AMR 
cases, endothelial injury correlated with a higher gene set expression of 
endothelial, NK cells and inflammatory genes and was associated also with a worse 
prognosis. In a further development of the study, the same group was able to 
identify an AMR selective gene set that discriminated patients with AMR from those 
without and included NK transcripts, endothelial activation transcripts, macrophage 
transcripts and transcripts involved in the IFN-γ response. These four gene sets 
showed increased expression with increasing pAMR grades [23]. Of note, a pilot 
analysis of gene expression profiling from our group shows that information gained 
from gene expression profiling are more closely related to parameters of graft 
function than is the diagnosis based on histology-immunohistochemistry alone [24].  
1.6.2 Antibodies: obscure bystanders or active players?  
 
By definition, antibodies are the key players in the pathogenesis of AMR. Yet, their 
detection is felt to be neither sufficient nor necessary to diagnose AMR and to start 
a specific therapy in heart recipients [16]. The introduction of multiplex-bead array 
assays has not only revolutionized the field of circulating HLA-Ab by greatly 
increasing the sensitivity in Ab detection [25], but also raised concerns regarding 
the specificity and clinical significance of some findings. The use of flow-cytometry 
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allowed detecting increased prevalence of pre-transplant allosensitized patients, 
thus improving the immunological characterization of heart transplant candidates 
[26]. These circulating HLA-Abs do have a prognostic relevance for post-transplant 
outcomes [27,28nn], but in some circumstances, such as in patients with mechanical 
assist devices, they do not seem to be clinically important after transplantation [29], 
and the risk/benefit ratio of desensitizing or avoiding forbidden antigens is still 
unclear [30].  
Several new reports show the prognostic relevance of de novo DSA in predicting 
the onset of clinical AMR [31], progression of cardiac allograft vasculopathy (CAV) 
[32,33] and overall survival [4,14]. However, it should be noted that not all DSAs 
are equal. Although HLA class I DSAs seem to be more important in assessing 
presensitization [25,34] and appear early after transplant [31], class II de novo DSA 
are more relevant in predicting pAMR onset and long-term mortality [4,31]. As 
outlined earlier, not all antibodies are complement fixing, thus when de novo DSA 
are found, clinicians should consider that the injury pathway elicited on the graft 
endothelial layer is variable and may have different time onset [3n, 8n]. Assay of the 
complement-fixing ability of DSA [35] may help to identify patients more likely to 
develop pathological evidence of complement-mediated injury in the EMB [36,37]. 
Current recommendations reasonably suggest active surveillance for de novo DSA 
after heart transplantation [25], although it is unclear how information gained from 
scheduled HLA-Ab assays should be handled. Given the controversial evidences 
regarding the risk/benefit balance of DSA management, to standardize our clinical 
practice we developed a multistep algorithm for the decision- making triggered by 
the detection of a de novo DSA, centered on differentiating the kind of antibody 
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involved, the clinical presentation and the time from transplant (Fig. 1).  
Clinical and pathological evidence of AMR may be found even in absence of HLA-
Ab, which may be at least partially explained either by the prozone effect or by 
presence of non-HLA-Ab. The prozone effect is caused by a high titer of circulating 
HLA-Ab, which may not revealed by the standard assay because the antigen beads 
become saturated and the HLA-Abs do not expose the Fc subunit to the secondary 
antibody. Prozone effect has to be ruled out either by diluting the serum or by 
adding Ethyl- enediaminetetraacetic acid (EDTA) [38 ]. Among the many types of 
non-HLA DSA, elevated levels of angiotensin-II type 1 receptor and endothelin type 
A receptor seem to be clinically significant in heart transplant setting, because they 
have been associated with early onset of CAV as well as with AMR and cellular 
mediated rejection. Non-HLA-Abs may be looked for when HLA-Abs are negative 
when AMR is highly suspected or may be used as biomarkers to stratify long-term 
risk of graft failure [39]. Nevertheless, current available evidence does not justify 
recommending active surveillance for non-HLA-Ab in heart transplant recipients.  
1.6.3 Graft dysfunction: imaging, symptoms or laboratory?  
 
AMR is a frequent cause of terminal cardiac graft failure [40], and it is reportedly 
associated with graft dysfunction and hemodynamic compromise in 10 – 47% of 
cases [1n]. However, the definition of cardiac allograft dysfunction is a clinical unmet 
need in heart transplantation medicine. Criteria for defining hemodynamic 
compromise have been highly variable in literature and include a decrease of left 
ventricular (LV) ejection fraction, elevation of intracardiac pressures with a 
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concomitant decrease of cardiac output (CO) and the need of inotropic therapy. 
Traditionally, allograft dysfunction is defined by echocardiographic criteria for right 
or LV systolic or diastolic dysfunction, with the latter usually preceding loss in 
ejection fraction [41n]. In particular, changes in systolic or diastolic function over 
time may be more clinically meaningful than absolute measurements to identify 
asymptomatic patients with possible manifestations of AMR [41n,42]. Right heart 
catheterization may help to identify increased ventricular filling pressure (i.e. 
diastolic dysfunction) as well as decreased CO. It has to be noted, however, that 
diastolic dysfunction may be a manifestation of chronic myocardial fibrosis not 
related to acute AMR, but to chronic coronary allograft vasculopathy (which in turn 
may be associated with DSA). Of note, myocardial fibrosis as assessed by late 
gadolinium enhancement is an important predictor of mortality, independently rom 
CAV, and may represent a meaningful marker of graft injury/dysfunction [43nn ]. In 
the effort to identify specific and non-invasive markers of ongoing rejection, recent 
studies pro- posed the detection of donor-derived cell-free DNA as a highly reliable 
marker for graft injury, being associated with biopsy-proven CMR and AMR [44,45]. 
Albeit preliminary, these findings sup- port the hypothesis that cell-free DNA could 
serve as a novel and reliable marker to trigger specific treatment for rejection and 
help to rule out nonspecific pathological abnormalities.  
1.7 Therapy for antiboby-mediated rejection: clinical 
case-based evidence 
 
When planning therapeutic strategies for AMR, it should be considered that 
appropriate induction; maintenance immunosuppression therapy and 
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immunological risk stratification are the key strategies to prevent de novo DSA 
onset. In addition to drug nonadherence, withdrawal of calcineurin inhibitors (CNIs) 
in patients at risk has been shown to increase AMR likelihood, whereas steroid 
withdrawal or utilization of mTOR inhibitors with low dose of CNI appears not to 
increase the risk [46n, 47].  
Regarding treatment of AMR, most of the evidence supporting any intervention is 
limited [2]. Most of therapies were originally designed to treat hematologic 
diseases, malignancies and auto- immune disorders, and thus the majority of 
treatments are off-label [1n]. The guiding principles for the treatment of AMR are 
based on targeting one or multiple steps involved in its pathological process and 
comprise: removal of circulating DSAs, reduction of additional DSAs, suppression 
T-cell and B-cell responses and inhibition of complement-mediated endothelial 
injury (Fig. 2). In light of the limited evidence available, the principle of caution 
justifies the use of aggressive strategies proportionally to the severity of clinical 
presentation. In particular, Intravenous immunoglobulines (IVIG) and plasma-
exchange/immunoabsorption appear to be effective in reducing DSAs burden with a 
good safety profile and are reported as first-line therapies [48,49]. Evidence based 
on small case series, expert consensus and established habits in clinical practice 
suggest that adding drugs targeting effector cells such as thymoglobulines, 
rituximab or bortezomib may not only improve efficacy in AMR treatment, but also 
increase the risk of infectious complication, thus restricting their use to AMR with 
severe clinical presentation or as rescue therapy after failure of first-line 
approaches [2,16,48 – 50]. Of note, in recent randomized trials, rituximab added to 
IVIG and plasma exchange failed to demonstrate ny additional benefit in kidney 
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transplant recipients with AMR [51] or in lung recipients with de novo DSAs [52]. In 
addition, the efficacy of these treatments is limited when AMR onsets later after 
transplantation [53].  
Compounds inhibiting complement activity raised high expectations, but 
randomized studies provided controversial findings. Eculizumab, a C5 complement 
inhibitor, failed to meet the efficacy endpoint of AMR and graft loss prevention in a 
randomized study in kidney transplant recipients [54n]. Conversely, the C1 esterase 
inhibitor Berinert appears to effectively revert DSA-mediated injury or prevent AMR 
in highly sensitized recipients in phase II studies [55,56].  
1.8 Conclusions 
 
Knowledge of AMR largely improved during the latest years, contributing to shade 
light on most of the circumstances in which the ‘biopsy negative’ rejection scenario 
was advocated. Molecular biology  
is improving pathology-based diagnosis, antibody testing is elucidating the role and 
significance of circulating antibodies and novel drug repurposing is improving 
therapeutic approach. The key message of this article is that current evidence 
support active surveillance for AMR, both by disorder and by serological criteria, at 
least as means to stratify prognosis and customize follow-up procedures. However, 
several unmet needs are still influencing clinical practice regarding the appropriate 
therapeutic approach for the different diagnostic scenarios: despite widely utilized in 
clinical practice, very limited evidence support current treatments for AMR. 
Collaborative and multiinstitutional studies are now needed to design evidence-
based approaches to prevent AMR onset and improve the outcome of patients with 
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AMR manifestations.  
1.9 Figure legends 
 
  
Figure 1. DSA detection represents a strong prognostic factor after heart transplant but it is not sufficient 
for the diagnosis of AMR and for planning a specific treatment. Indeed, there is no clear evidence of a benefit 
deriving from changes in patient management subsequent to information gained by DSA monitoring. 
Nevertheless, we believe that the possibility of DSA onset should not be ignored and thus we framed this 
decision-making algorithm, which takes into consideration the association of DSA with symptoms and pAMR, 
timing of DSA onset/detection and complement binding ability. When DSA onset is within the first years after 
transplantation, they are more often associated with acute rejection responding to treatment. Late onset 
DSA, in particular when not associated with complement binding activity, may lead to chronic injury, initially 
difficult to diagnose, that may express with CAV development. This may justify not performing EMB in 
asymptomatic patients with late onset DSA, but may support the need for a low-toxicity therapy such as 
intravenous immunoglobulines. The association of DSA with pAMR findings on the other hand, justifies 
specific treatment, in particular if associated with signs of graft dysfunction. HT: heart transplant; DSA Donor 
specific antibodies; EMB: endomyocardial biopsy; C1q: complement binding activity; MFI mean fluorescence 
intensity.  
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Figure 2. Antigen presenting cells, B-cells, CD4 T-Cells, plasma cells, immunoglobulines, NK cells, 
macrophages, and complement proteins compose a complex and interactive scenario in which graft injury 
may occur. NK cells and macrophages may elicit complement independent graft injury, trans-activated by 
DSA and by inflammatory chemochines produced by endothelial cells upon the binding of the DSA (see 
references 8 and 12). As indicated in the figure, each of these steps may represent a therapeutic target of 
one or multiple drug strategy. Intravenous immunoglobulines have multi-target action as anti-inflammatory, 
immune-modulators, complement inhibition and by suppressing exposure of HLA class I and II.  
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PART II 
 DEFINITION OF CLINICAL AND IMMUNOLOGICAL 
PHENOTYPES OF ANTIBODY MEDIATED 
REJECTION IN HEART TRANSPLANT RECIPIENTS: 
PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 
 
“CLIN-Heart project” Interventional non-pharmacological prospective study 
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2.1 Introduction 
 
Heart failure is a chronic medical condition that affects more than 6.5 million people in 
Europe and is one of the most frequent causes of hospitalization in adult population. In a 
select group of end-stage patients, heart transplant is considered the treatment that 
provides the best benefit in terms of survival. During the least 4 decades short- and long-
term mortality was significantly reduced with a median survival that actually exceeds 11 
years. In particular this improvement is correlated with an increased survival during the 
first year after surgery, together with a modest change in the annual risk from that point on, 
and it is mainly related with both improvements in perioperative management and new 
immunosuppressive regimens which have decreased the prevalence of acute rejection in 
the early period.1,2  
Despite these impressive results, data from the ISHLT (International Society for Heart and 
Lung Transplantation) Registry reported that the graft dysfunction (GD), which includes 
both coronary graft vasculopathy (CAV) and episodes of rejection (cell-mediated (CMR) 
antibody-mediated (AMR) and mixed), causes approximately 40% of deaths after the first 
5 years after surgery 3. (Figure 1) 
Late post-transplantation acute graft dysfunction is less frequent than chronic presentation 
which is usually characterized by a slow and progressive onset of diastolic abnormalities 
accompanied by slight decrease in ejection fraction and worsening heart failure symptoms. 
In literature the graft damage mediated by AMR is one of the main mechanisms leading to 
graft dysfunction in the post-transplant but, while for the CMR diagnosis is established on 
the basis of histological staging on endomyocardial biopsy (EMBs) and it is typically 
treated with the common immunosuppressive drugs, the diagnosis of AMR is much more 
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complex. According to ISHLT guidelines, the latter is based on the presence of the 
following criteria: signs / clinical symptoms of cardiac dysfunction, evidence of anti-HLA 
antibodies against the donor (donor specific antibodies, DSAs), and immunohistochemical 
and pathological findings on biopsy 3. 
It has been show that AMR is followed by increased graft loss, cardiac allograft 
vasculopathy (CAV), and death.
4–6
A consensus report from an ISHLT task force 
references previous works where, while early AMR was associated to graft dysfunction in 
68% of patients, in late AMR, only 13% was hemodynamically significant. Moreover, a pair 
of recent single-centre studies demonstrated that late AMR (>1 year after transplant) 
featured a 1-year mortality of 50% to 53%.
7,8 
This complexity is also underlined by the fact that, in some cases, the presence of typical 
pathological findings of CMR and AMR in the same sample biopsy has been reported. This 
suggests the possible correlation between the humoral and cellular branch of the immune 
system.  
Finally another common and typical cause of GD is CAV, which can be considered as a 
form of chronic vascular rejection. Typically, CAV development is triggered by metabolic 
risk factors – as well as native coronary atherosclerosis – and by immune-mediated injury, 
including antibody-mediated endothelial injury (indeed, CAV may be a chronic phenotype 
of AMR). CAV is characterized by diffuse intimal hyperplasia arising from peripheral 
vessels and spreading to proximal tracts of arteries and veins, thus determining diffuse 
luminal narrowing, often without focal luminal stenoses.9 
In this study we aimed to characterize clinical phenotypes of patients with GD, either acute 
or chronic expression, comparing their outcomes with stable patients. In addition, we 
explored the risk factors for outcome in GD patients focusing our attention on the allo-
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immune response of the graft. 
 Figure 1 from The Pathology of Cardiac Transplantation (page 156) 
  
 
 
  
2.2 Aim of the study 
 
Despite its clinical relevance, there is a lack of consensus regarding the definition of 
graft dysfunction (GD) in heart transplant (HT). This project is based on a prospective 
non-interventional clinical study in which we aimed to characterize clinical phenotypes of 
patients with GD, either acute or chronic, comparing their outcomes with stable 
patients.  
 
Primary objective of the study: 
- Identify the clinical and subclinical phenotypes of patients that define the presence of 
graft dysfunction and correlate these characteristics with subsequent cardiovascular and 
non-cardiovascular events and mortality. 
Secondary objectives of the study: 
- Understanding the most significant risk factor that predict mortality and cardiovascular 
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events in the subgroup of heart transplant patients with signs or symptoms of graft 
dysfunction, focusing our attention on the allo-imune response and the presence of donor 
specific antibodies (DSAs) or humoral rejection. 
2.3 Study design 
 
The project was set up as single centre, non-interventional controlled study, in patients 
who underwent heart transplant. All consecutive patients enrolled have been divided in 
three different groups. 
- GROUP A: Patients who underwent heart transplantation within less than five years, who 
received endomyocardial biopsies (EBMs) according to the clinical practice followed at our 
Centre (the current clinical monitoring protocol involves performing EBMs for monitoring of 
cellular rejection until the fifth year post-transplant) 
- GROUP B: Patients with clinical and instrumental signs of graft dysfunction, regardless of 
the distance of the transplant. GD was defined as at least one of the following: left 
ventricular ejection fraction (LVEF)<55%, symptomatic cardiac allograft vasculopathy 
(CAV), or new onset symptoms of heart failure. These patients may be subjected to an 
EBM, only if deemed clinically necessary, in order to exclude the presence of rejection. 
- GROUP C: Stable patients with a period free of rejection events exceeding 5 years and / 
or which do not require high therapeutic regimens with immunosuppressive drugs in post-
transplant maintenance. It is expected that this group of patients have no clinical need for 
control EBMs. 
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2.4 Methods 
 
2.4.1 Study population  
 
Inclusion criteria:  
• Heart transplanted patients included in the following categories: 
A) Patients who had received a control EBM according to the protocol applied in our 
Centre  
Or 
B) Patients who presented clinical signs or symptoms of graft dysfunction  
Or 
C) Patients immunologically "stable" for over 5 years, with normal function of the graft 
 
• Signature of informed consent 
• Age ≥ 18 years 
Exclusion criteria: 
• Multiorgan transplant 
2.4.2 Clinical assessments 
 
V1- Baseline evaluation 
In Group A, the “per-protocol” EBM represented our index evaluation. For Group B and 
Group C patients, V1 coincided with one of the outpatient clinical controls, when the 
patient will sign informed consent to participate in the protocol. 
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Biopsies and clinical visits in accordance with the guidelines approved at our transplant 
Centre respect the following protocol: 
• 1 month 1 biopsy / week 2 visits / week 
• 2-3 months 1 biopsy / 15 days 1 view / week 
• 3-6 months biopsy 1 / month 1 view / 15 days 
• 6-12 months biopsy 1/2 months 1 visit / month 
• 1-2 years biopsy 1/4 months 1 view / 2 months 
• 2-5 years 1 biopsy / 1 view 6 months / 3 months 
• > 5 years 1 view / 3-4 months 
During the baseline evaluation every patients underwent a complete clinical and 
instrumental assessment which included: the collection of demographic data and the 
previous medical history, physical examination, resting ECG, transthoracic 
echocardiography, standard laboratory tests and right heart catheterization (only in 
patients who underwent EBMs).  
Finally the evaluation of the humoral response against the graft was performed by using 
specific laboratory tests that dose the titre of anti-HLA antibodies (DSAs or non DSAs) in 
serum samples. 
Follow-up visits: 
Clinical follow-up controls were organized at intervals of 6 months (+/- 2 weeks). During 
each visit we collected: physical examination data, resting ECG, echocardiography, blood 
tests, antibodies HLA and non-HLA dosages. We also performed additional laboratory test 
on blood samples at 1 month (M1), 3 months (M3) and 9 months (M9) (See table 1). 
Biopsies will be repeated for patients in group A on the basis of our protocol (see above). 
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Table 1 
 
*  Group A patients received a EBMS on the basis of our standard clinical assessment, 
while group B and C patients, EBMs have been performed only for clinical indications to 
rule out the presence of rejection. 
 
2.4.3 Standard Procedures 
 
• Laboratory tests: we performed normal routine blood tests (i.e. complete blood 
count, renal and liver function, lipid profile, sodium, potassium, glucose etc.)  
• Evaluation of CAV: The presence of CAV is routinely detected by intracoronary 
ultrasound (IVUS) and angiography at 1 month, 1 year, and 5 years after heart 
transplant. Thereafter the evaluation is repeated at 5-year intervals when there are 
not controindications. 
• Evaluation of EBMs specimens and histological grading: Serial sections of 
endomyocardial samples, are usually stained with hematoxylin-eosin to assess the 
follow	up	(every	6	months	(	
+/-	2weeks)	
V1	
Baseline	
M1	 M3	 V2	
M6	
M9	 V3	
M12	
V4	
M18	
V5	
M24	
Informed	Consent	 X		 	 	 	 	 	 	 	
Right	Heart	
Catheterization/	EBMs	
X	
	 	
X	
	
		X	 X	 X	
Clinical	Evaluation	 X	 	 	 X	 	 X	 X	 X	
ECG	 X	 	 	 X	 	 X	 X	 X	
Ultrasounds	 X	 	 	 X	 	 X	 X	 X	
Laboratory	tests	 X	 		X	 X	 X	 X	 X	 X	 X	
HLA-antibodies		 X	 	 	 X	 	 X	 X	 X	
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degree CMR according to the Working Formulation of ISHLT 2005. According to the 
ISHLT 2011 recommendations, AMR pathological grading is established basing to 
histopathology findings of microvascular inflammation (intravascular mononuclear 
cells and endothelial cells) and immunohistochemical findings (capillary C4d 
deposits in more than 50% of vessels). 
AMR pathological grading: 
pAMR 0 = absence of histopathological and immunohistochemical findings. 
pAMR  1 = positive histopathological findings or positive immunohistochemical 
pAMR  2 = histopathological and immunohistochemical both positive 
pAMR  3 = evidence of histopathological findings of severe damage (e.i. Interstitial 
haemorrhage, extensive fragmentation, mixed inflammatory infiltrate) 
2.4.4 Specific study procedures 
 
• HLA antibodies detection in venous blood samples (every 6 months)	IgG anti-HLA 
reactivity in the sera was tested with a bead-based screening assay (LABScreen 
mixed kit -One Lambda) which simultaneously detects class I and class II 
antibodies with microbeads coated with purified class I and class II HLA antigens. In 
case of positivity the serum have been analysed on the Luminex platform with the 
same LABScreen Single Antigen test, which employs beads labelled with a specific 
antigen, both class I and class II. The technique and software used are the same. 
The results will be interpreted using the MFI values (Normalized Mean 
Fluorescence Intensity). The cut-off in positive test is represented by a value higher 
than 1000 MFI. These analyses allow detecting the presence of anti-HLA 
immunoglobulins, regardless of their ability to fix complement. 
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2.4.5 Evaluation of results 
 
Outcomes Mesures 
- Overall mortality in group A, B and C. 
- Hospitalizations for cardiovascular events (CV hospitalizations) 
- Hospitalization for non-cardiovascular events (non-CV hospitalizations) 
 
Combined Endpoints 
- Death or/and CV hospitalizations  
 
2.4.6 Statistical Analysis 
 
Statistical analyses were performed using JMP 7.0 (SAS Institute, Cary, NC, USA). 
Baseline characteristics in the three groups were compared using, as appropriate, 
Student’s t-test, ANOVA or Chi-square test. Outcome data and survival were calculated 
using Kaplan-Meier method with the Long-rank test.   
Risk factors, associated with clinical events, have been analysed by Cox analysis and 
statistical regression models. 
All statistical analyses were conducted at significance level of 0.05. All continuous 
variables were reported by mean and standard deviation, or by median and interquartile 
range in case of skewed distribution. Nominal variables were expressed as a number an 
percentages. 
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2.5 Results 
 
2.5.1 Baseline comparison between group A, B and C 
 
We enrolled a total of 134 consecutive heart transplant (HT) patients followed in our 
department between November 24th 2014 and April 28th 2016. 62 patients have been 
included in group A (46%), 32 (24%) in group B and 40 (30%) patients in group C. 
All clinical and laboratories data were collected during the scheduled visits and our date of 
last follow-up was December 1st 2016. 
The median age of our total population was 60 years [50 - 68], 31% were female and the 
most frequent causes for heart transplant were ischemic disease and dilated 
cardiomyopathy which respectively occurred in 26% and 37.4% of cases. 
In table 2 we show some clinical variables to highlight the principal baseline differences 
between the three groups of enrolment. Patients in group B and in group C had a longer 
time distance from heart transplant and were older respect group A (respectively 146 [88 - 
206] months and 202 [150 - 234] months vs. 11.98 [0.43-42.5]; p<0.01). The median age 
was 65.6 [58.6- 72.5] in group B, 67.4 [56.8 – 74.5] in group C vs. 55.1 [44.6 -60.9] in 
group A (p<0.01). Moreover in Group B, defined as the group of patients with signs or 
symptoms of graft dysfunction, there was an significantly higher percentage of patients 
with a class NYHA > II (71.9%, p<0.01) and showed a significantly lower LVEF (59.4% in 
group B had a LVEF<55%; p<0.01) respect to the other two groups. 
Moreover, in group B we found a significantly higher percentage of patients with positive 
Donor Specific Antibodies (DSAs) (p=0.05) at the time of enrolment but no differences 
were showed for non-DSAs HLA-antibodies. A higher prevalence of CAV (59.4%) were 
detected in group B, even if for 18 patients the angiographic evaluation was not available 
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(p<0.01). 
The number of cases of non-CV-hospitalization and of CV hospitalizations, during the first 
year before the time of enrolment (V1), in group B was higher respect group A and C 
(respectively p=0.03, p<0.001). 
Finally ECG performed at V1 showed in group B had a longer duration of QRS and QTc, 
and a higher number of cases of patients with low-voltage ECG. 
Table 2 Baseline characteristics in group a, B and C. 
All 
(N= 134) 
GROUP A 
(N= 62) 
GROUP B 
(N= 32) 
GROUP C 
(N= 40) 
P 
Aetiology: 
CAD 
DCM 
Others 
 
19 (30.7%) 
18 (29%) 
25 (40.3%) 
 
10 (31.3%) 
13 (40.6%) 
9 (28.13%) 
 
6 (15%) 
19 (47.5%) 
15 (37.5%) 
 
0.2 
 
 
Time after HTx 
(months) 
 
11.98 [0.43-42.5] 
 
146 [88 - 206] 
 
202 [150 - 234] 
 
<0.001 * 
Female sex 23 (37.1%) 8 (25%) 11 (27.5%) 0.4 
Age (years) 55.1 [44.6 -60.9] 65.6 [58.6- 72.5] 67.4 [56.8 – 74.5] < 0.001 * 
NYHA >II 9 (14.5%) 23 (71.9%) 11 (27.5%) < 0.001  
LVEF<55%  0 19 (59.4 %) 0 < 0.001 
Positive DSAs 4 (6.5%) 7 (21.9%) 3 (7.5%) 0.05 
Positive non- DSAs 9 (14.5%) 5 (15.6%) 2 (5%) 0.28 
CAV 11 (17.7%) 19 (59.4%) 8 (20%) <0.01 
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CAD: Coronary Artery Disease, DCM: Dilated Cardiomyopathy, Others: Hypertrophic Cardiomyopathy, 
Restrictive cardiomyopathy, Right ventricular arritmogenic cardiomyopathy, Post-myocarditis 
cardiomyopathy, Post-chemotherapy cardiomyopathy, LVEF: Left Ventricular Ejection Fraction, DSAs: Donor 
Specific Antibodies, non-DSAs: non Donor Specific HLA antibodies, CAV: coronary graft vasculopathy, 
Events pre V1: non CV hospitalizations pre V1, CV Events: CV hospitalizations pre V1 
 
2.5.2 Outcomes 
 
Patients with graft dysfunction (group B) during the 2 years of follow up had a worse 
prognosis. As it is shown in Figure 1, the mortality rate after 24 months was 23% while in 
Group A and C were 15% and 13% respectively (p=0.05). 
Moreover Group B patients had a higher incidence of CV hospitalizations and non-CV 
hospitalizations compared with the other two groups (Figure 3 and 5). 
The most common cause of CV hospitalization was graft rejection in the 30.7% of the 
cases (2 cases were diagnosed as AMR in group B and 2 cases were episodes of ACR 
one in group A and one in group B).(Figure 4.a, 4.b,4.c) 
 
 
 
Non-CV Events pre-V1 2 (3.2%) 5 (15.6%) 1 (2.5%) 0.03 
CV Events pre V1 11 (17.7%) 16 (50%) 3 (7.5%) < 0.001 
QRS (msec) 103 ± 21 131 ± 34 106 ±19 <0.001 
QTc (msec) 448 ± 19.7 474 ± 30 445 ± 25 <0.001 
Low-voltage ECG 
(mVolt) 
6 (12%)           9 (36%) 2 (6%) <0.001 
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Figure 1 :Overall survival in Group A, B and C 
 
 
p= 0.05 
 
 
Figure 2: Freedom from non-CV hospitaliaztion  
 
 
 
p= 0.83 
 
Figure 3: Freedom from CV hospitalizations 
 
 
 
p <0.001 
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Figure 4.a: Causes of CV hospitalizations 
 
 
 
 
 
Figure 4.b: Causes of CV hospitalizations in group B 
 
 
 
Figure 4.c: Causes of CV hospitalizations in group A 
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Freedom from Combined Endpoint 1 (death or/and CV hospitalizations) 
 
 
 
p< 0.001 
 
 
2.5.3 Sub group Analysis: Risk factor for death or/and CV 
hospitalizatios (Combined Endpoint) 
 
Clinical presentation of GD in group B was highly heterogeneous: 19% of patients had an 
acute presentation (3 for acute rejection, and 3 for acute coronary syndromes); 66% had 
chronic presentation: 17(53%) associated with CAV, and 4(13%) as chronic dysfunction 
after antibody-mediated rejection. 5 patients had acute symptoms but no-graft related 
cause emerged.  
Low EF, time from HT, and chronic clinical presentation (p=0.04, p=0.05 and p<0.01) were 
risk factors for the combined endpoint, in particular no patients with an acute GD died or 
was hospitalized for CV in the follow up. (Table 3) 
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Table 3 Risk factors for death and or CV hospitalizations 
Cox regression model 
Group  B (n=32) RR Lower 95%- upper 95% p 
Years from HT 1.08 1.00-1.18 0.05 
LVEF<55% 4.19 1.09-27.45 0.04 
NYHA>II 2.70 0.7-17.66 0.15 
CAV 0.38 0.10 – 1.22 0.1 
Chronic GD n.a.* n.a. <0.001 
DSAs 1.34 0.35-4.28 0.64 
* None of the patients with acute presentation of GD had any endpoint event, vs. 40% of those with chronic 
presentation of GD. Lack of events in the acute GD group does not allow to calculate relative risk.  
2.6 Discussion 
 
This prospective study tried to investigate the clinical impact of GD in patients who 
underwent heart transplant in terms of survival and cardiovascular outcomes. 
The prevalence of GD in our population was 24%. The 18.8% of patients with GD had a 
GD within 5 years after transplant; in the half of these cases they had an acute rejection. 
The rest of patients had a GD more than 5 years after transplant, and the major cause of 
GD was related to CAV (65.4%), while rejections in the late post-operative period 
represented the 19% and were more frequently due to a chronic AMR.  
Moreover GD had two different clinical presentations. 21.8% patients had an acute 
expression related to acute rejections or acute coronary syndrome (5 patients had acute 
symptoms but no-graft related cause emerged).  
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After acute GD, patients recovered completely or with minimal clinical consequences, no 
combined endpoint was recorded.  
The majority had a chronic presentation, with a persistent reduction LVEF, and the most 
frequent cause was CAV (53%) while the 13% had a GD related to chronic AMR (3 
patients) and in only one case had a mixed rejection (1 patient). Ten of these patients 
showed at least one combined enpoint (death or /and CV hospitalization). 
It should be noted that it was not possible to analyse separately the causes of death 
because in some of the cases the cause of death was unclear. 
Only 5 patients of our total population had a clear episode of antibody-mediated rejection 
(AMR) and 4 of them had a chronic dysfunction and were not transplanted recently (<5 
years). All 4 of them belonged to group B: only two out of these 4 patients had the 
combined endpoint 2. 
Other 3 patients in group A (< 5 years from heart transplant) who underwent EBMs 
showed a positive pAMR and positive DSAs but without hemodynamic compromise. All of 
them didn’t present our Combined endpoint 2. 
These data seems to confirm the findings of Kevin J. et al in retrospective study published 
in 2016. In their article, they observe that late AMR is frequently associated with graft 
dysfunction, and when graft dysfunction is present with late AMR, there is a significantly 
increased mortality and rapid development of CAV despite aggressive treatment compared 
with all other groups of AMR 1. 
2.7 Conclusions 
 
GD after HT is correlated with a worse outcome and survival, in particular when the GD 
had a chronic clinical presentation. AMR had a low incidence in our population, with a 
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selective clinical impact. DSAs did not seem to be a good predictor of death or 
cardiovascular events in the group of patients with GD. 
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3.1 Introduction 
 
The achievement of an optimal balance between adequate protection from rejection and 
the adverse consequences of over-immunosuppression (i.e. infections and metabolic 
toxicities of drugs) is a pivotal, yet fully unmet need in clinical practice after heart 
transplant. Note that according to ISHLT registry infectious death is more frequent than 
rejection death (Figure 1)  
In recent years, several laboratory tests have been used in medical research in order to 
assess the state of immune activation in patients undergoing solid organ transplant, one of 
the most used is the Cylex ImmunoKnow test. This method measures the amount of 
adenosine triphosphate produced by activated CD4 + T lymphocytes after stimulation with 
some reagents (phytohemagglutinin). 
A strong response implies that transplant immune-compromised patients have a high risk 
of rejection, and a low response reflects a high level of immunosuppression with an 
increased risk of infections. Different studies confirm these results, but the method lacks 
high sensitivity since it cannot quantify the magnitude of the innate immune response. 
Lately, a new laboratory tests, the QuantiFERON Monitor (QFM), has been introduced. It 
measures the plasma production of interferon-gamma after incubation of heparinized 
blood sample by stimulating both the innate immune system (R848) and the acquired 
immune system (CD3). However, to date, this test has never been studied in the context of 
heart transplantation, and it is not known whether it is able to provide additional 
information respect to the consolidated "Cylex". 
Thus, we tested the clinical applicability of a novel immune monitoring test – QFM - 
developed to detect conditions of over- or under- immunosuppression after heart 
transplant, focusing our analysis on infectious risk. 
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Figure 1: ISHLT registry: adult heart transplants relative incidence of leading cause of death 
 
3.2 Aim of the study 
 
In this study we used the QFM test in a group of patients enrolled in the CLIN-heart 
protocol to analyse the impact of this novel immune monitoring essay on the risk of 
infection in the 3-6 months subsequent to the essay. 
3.3 Methods 
 
3.3.1 Population 
 
We enrolled a group of heart transplanted patients who were already part of one of the 
three enrolment groups (A, B, C), previously described in the CLIN-heart Protocol (Part II). 
These patients had to fit the sub-sequent criteria. 
Inclusion criteria: 
• Patients aged ≥ 18 years 
• Signing of informed consent 
Exclusion criteria: 
• Patients not compliant to immunosuppressive regimens. 
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• Patients treated with interferon-gamma. 
• Combined transplantation. 
3.3.2 QFM test 
 
This method measures interferon (IFN)-gamma production in plasma, after incubation of 
heparinized blood, with innate (R848) and adaptive (CD3) stimulants. High doses of INF- 
line reflect a more intense immune response. 
The first QFM test detection coincided with the baseline assessment (V1) of CLIN-heart 
protocol; subsequently patients were followed for 3 to 6 months and the incidence of 
infection was assessed. 
 
3.3.3 Endpoints 
 
• Any infection as recorded clinically during the visit or reported by the patient 
including: 
- High temperature with clinical symptoms 
- CMV isolates needing treatment (>10,000 DNA copies/ml) 
- Gastroenteritis with systemic implications in the context of epidemic season, 
even with no fever 
• Infection etiology is supposed based on a microbial isolate, when available, or on 
the most likely outcome of the clinical course (I.e. a respiratory syndrome with fever 
resolving with antibiotics is regarded as bacterial; a flu-like syndrome with 
gastroenteritis self resolving is regarded as viral). Weakness: overlapping 
syndromes cannot be definitely elucidated 
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3.3.4 Statistical analysis 
 
Statistical analyses were performed using JMP 7.0 (SAS Institute, Cary, NC, USA). 
QFM results are reported as median [25th-75th percentile]. To identify a cut-off value we 
used ROC analysis and median values were compared using Student’s t-test. 
3.4 Results 
 
We enrolled 128 patients, whose main characteristics were: 57 ±14 y old, 67% males, with 
60±10% ejection fraction, with a median time from transplant of 5 [ 1-16 ] years after heart 
transplant. 
For 106 patients with at least 3-months follow-up, we recorded 32 (30%) infectious 
episode in the subsequent 3 to 6 months. QFM results showed a wide variability in the 
study patients, with a median (range) value of 104 [30-517] IU/ml of IFN-g.  
Patients developing clinical manifestations of infections had QFM result significantly lower 
than those without infections (45[12-84] vs.176 [43-664] IU/ml; P<0.01). Figure 2 shows 
that patients with viral infections had a lower QFM value with respect to patients with 
bacterial infections. Of note, all the 3 infections in the high QFM group were related to self-
resolving viral syndromes.  
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Figure 2: Baseline QFM and subsequent infection (N= 106 patients): QFM and infection 3-6 
months later.  
 
Figure 3:  Time from heart transplant and QFM (n=128 patients) 
 
Although patients at less than one year after HT had significantly lower QFM test than 
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those at longer follow-up, the predictive ability of QFM on the risk of infection persisted 
significantly after adjusting for post-HT follow-up (Table 1). 
Table 1: QFM>100 adjusted for possible confounders 
 OR 95% C.I. p 
QFM > 100mU/ml 6.76 1.87 – 32.5 <0.01 
Time from HTX (per y) 1.02 0.94 – 1.09 0.9 
Lymph count 2.18 0.68 – 7.92 0.4 
 
By ROC analysis, we identified a cut-off of 100 IU/ml to discriminate the subgroup at 
higher risk of infection: 58.9% of patients with QFM<100 developed infections vs. 15.3% of 
those with QFM ≥100 IU/ml (P<0.05). (Figure 4) 
Figure 4:Era specific QFM threshold (QFM≥ 100 IU/ml) and rate of subsequent infection 
 
3.4.1 Infection recurrence and QFM 
 
We performed a second detection of QFM recording subsequent infective episodes. We 
found that patients with a “relapsing episode of infection” (with an infection both before and 
after the second QFM) and patients with a new onset infection (only post the second QFM 
test) showed lower values with respect to the group free from infections and the group who 
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had a previous (pre-second QFM) infection but recovered completely (p<0.01) (Figure 5) 
Figure 5: infection recurrence and QFM 
 
As it is shown in the sequent Figure 6, infection events may boost immunity at follow-up 
assay: in fact we have higher values of QFM in particular in patients who recovered from 
infection. 
The change of QFM doesn’t seem to predict subsequent infection. (p=0.3) 
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Figure 6: infections boost QFM 
 
3.5 Discussion and conclusions 
 
This study provides first suggestive evidence that a novel immune-monitoring method of 
IFN-g assay after stimulation of innate and adaptive immunity may identify HT recipients 
with low responsiveness of immune system and high risk of infection (more reliable after 
early period) and it seem possible to identify a definite threshold of risk which could be 
different in early and late post- transplant recipients. Moreover QFM essay seems to be 
useful in detecting progressive immune reconstitution after transplantation. We need of a 
large number of cases to assess if it is a true representation of the wide variability in 
immune response ability or if it is al limit of the assay. 
Further analysis is needed to assess the effect of therapy modulation on QFM and the 
relationship with acute rejection episodes and the sensitivity of the assay to changes in 
immunosuppressive drugs. Finally it could be interesting improving the knowledge of the 
immune-mechanisms beyond the response of the assay in correlation with T-cells 
subpopulations. 
